METEORIC-HF Phase III trial of Omecamtiv mecarbil opens enrollment for treatment of heart failure. Amgen + Cytokinetics + Servier

Amgen, Cytokinetics Incorporated and Servier announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase III clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF).

METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF. Cytokinetics is conducting METEORIC-HF in collaboration with Amgen , with funding and strategic support from Servier.

Comment: Omecamtiv mecarbil is the subject of a comprehensive Phase III clinical trials program comprised of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), a large, Phase III global cardiovascular outcomes study, and METEORIC-HF. Amgen is conducting GALACTIC-HF in collaboration with Cytokinetics and Servier.